Dr. Gregory Sivolapenko qualified in Pharmacy from the University of Athens in 1984 and obtained his Ph.D. in Medicine (Immunology and Clinical Oncology) from the Royal Postgraduate Medical School (currently Imperial Medical School), University of London, UK, in 1990.
During the period 1985-1990 he had worked as Research Fellow at the Hammersmith Hospital in London and at the Imperial Cancer Research Fund (UK).
Over the last twenty-five years, Dr. Sivolapenko has researched in the UK and Greece, with particular interest in tumour targeting using monoclonal antibodies and novel anti-cancer peptides in pre-clinical and clinical setting.
His basic and clinical research has resulted in a large number of publications at international medical journals and books. Dr. Sivolapenko has presented his studies as invited speaker at many international medical conferences and meetings. In recognition of his innovative research projects Dr. Sivolapenko has been awarded patents, and also received grants from several bodies including the Cancer Research Campaign (UK), KESY & ESPA (Greece).
Dr. Sivolapenko has gained international pharmaceutical product development and international medical/marketing experience through his employment and/or advisory position in a number of pharmaceutical companies. He is founding member and member of the board of directors of several pharmaceutical and research companies. Dr. Sivolapenko is also a member of the European Forum of Good Clinical Practice and participates at the Ethics Committees steering group. Since March 2006, Dr. Sivolapenko holds the position of Associate Professor at the Dept. of Pharmacy and Head of the Pharmacokinetics Laboratory, University of Patras, Patras, Greece.
